DXC Technology Reports Q4 Loss, Continued Organic Revenue Decline, and Weak FY27 Guidance
Summary
DXC Technology reported a Q4 GAAP loss and a 6.6% organic revenue decline, with full fiscal year 2026 organic revenue down 4.8%. The company issued weak guidance for Q1 and full fiscal year 2027, projecting further organic revenue contraction and lower EPS and free cash flow.
Key Events
-
Q4 FY26 Financial Performance
Reported a GAAP diluted loss per share of $(0.84) and non-GAAP diluted EPS of $0.77, down 8.3% year-over-year. Total revenue was $3.13 billion, a 6.6% organic decline year-over-year, which is worse than the previous quarter's organic decline.
-
Full Fiscal Year 2026 Results
Achieved $713 million in free cash flow, up 3.8% year-over-year, and repurchased $250 million of shares. However, full-year organic revenue declined by 4.8%, and GAAP diluted EPS was $0.10, down 95.2% year-over-year.
-
Weak Q1 FY27 Guidance
Projected Q1 FY27 total revenue between $2.97 billion and $3.00 billion, representing a 7.5% to 6.5% organic decline, and non-GAAP diluted EPS of approximately $0.40, significantly below Q4 FY26 results.
-
Lowered Full FY27 Outlook
Provided full fiscal year 2027 guidance with total revenue in the range of $12.11 billion to $12.35 billion (a 5.0% to 3.0% organic decline), non-GAAP diluted EPS between $2.40 and $2.90, and free cash flow of approximately $600 million, all indicating a decline from FY26.
Analysis
DXC Technology's latest earnings report reveals a challenging operational environment with a significant GAAP loss in Q4 FY26 and a persistent organic revenue decline that is projected to worsen in Q1 FY27. While the company maintained strong free cash flow in FY26, the guidance for FY27 indicates a notable reduction. The lowered EPS and EBIT margin guidance for the upcoming fiscal year suggest ongoing profitability pressures. This report confirms a negative trend in the company's core business, which is particularly concerning as the stock is already trading near its 52-week low. Investors should anticipate continued headwinds and monitor the company's ability to stabilize its top-line performance and improve profitability.
At the time of this filing, DXC was trading at $9.95 on NYSE in the Technology sector, with a market capitalization of approximately $2B. The 52-week trading range was $11.07 to $17.26. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.